These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 15567754

  • 1. The ratio of MMP-2 to TIMP-2 in hilar cholangiocarcinoma: a semi-quantitative study.
    Xiao M, Zhou NX, Huang ZQ, Lu YL, Chen LH, Wang DJ, Chang WL.
    Hepatobiliary Pancreat Dis Int; 2004 Nov; 3(4):599-602. PubMed ID: 15567754
    [Abstract] [Full Text] [Related]

  • 2. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.
    Terada T, Okada Y, Nakanuma Y.
    Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
    Sogawa K, Kondo K, Fujino H, Takahashi Y, Miyoshi T, Sakiyama S, Mukai K, Monden Y.
    Cancer; 2003 Nov 01; 98(9):1822-9. PubMed ID: 14584061
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemical expression of matrix metalloproteinases 1 and 2 (MMP-1 and MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in ruptured and non-ruptured tubal ectopic pregnancies.
    Kucera E, Tangl S, Klem I, König F, Grossschmidt K, Kainz C, Sliutz G.
    Wien Klin Wochenschr; 2000 Sep 15; 112(17):749-53. PubMed ID: 11042903
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
    Pesta M, Holubec L, Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Kormunda S, Elgrova L, Finek J, Cerny R.
    Anticancer Res; 2005 Sep 15; 25(5):3387-91. PubMed ID: 16101153
    [Abstract] [Full Text] [Related]

  • 9. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers.
    Mwaura B, Mahendran B, Hynes N, Defreitas D, Avalos G, Adegbola T, Adham M, Connolly CE, Sultan S.
    Eur J Vasc Endovasc Surg; 2006 Mar 15; 31(3):306-10. PubMed ID: 16169261
    [Abstract] [Full Text] [Related]

  • 10. Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors).
    Schmitz KJ, Lang H, Kaiser G, Wohlschlaeger J, Sotiropoulos GC, Baba HA, Jasani B, Schmid KW.
    Hum Pathol; 2009 Dec 15; 40(12):1706-14. PubMed ID: 19683330
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Correlation between expression of MMP-2, MMP-9, TIMP-2, TIMP-1 and metastasis of neuroblastoma].
    Cheng Y, Dong Q, Sun LR, Yang CM, Jiang BX.
    Zhonghua Zhong Liu Za Zhi; 2005 Mar 15; 27(3):164-6. PubMed ID: 15946567
    [Abstract] [Full Text] [Related]

  • 13. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
    Morán A, Iniesta P, García-Aranda C, De Juan C, Díaz-López A, Sánchez-Pernaute A, Torres AJ, Díaz-Rubio E, Balibrea JL, Benito M.
    Oncol Rep; 2005 Jan 15; 13(1):115-20. PubMed ID: 15583811
    [Abstract] [Full Text] [Related]

  • 14. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters.
    Giannopoulos G, Pavlakis K, Parasi A, Kavatzas N, Tiniakos D, Karakosta A, Tzanakis N, Peros G.
    Anticancer Res; 2008 Jan 15; 28(3B):1875-81. PubMed ID: 18630474
    [Abstract] [Full Text] [Related]

  • 15. Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma.
    Cavalheiro BG, Junqueira CR, Brandão LG.
    Arch Otolaryngol Head Neck Surg; 2009 Aug 15; 135(8):812-7. PubMed ID: 19687404
    [Abstract] [Full Text] [Related]

  • 16. Expression of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in intraductal and nonintraductal growth type of cholangiocarcinoma.
    Jo Chae K, Rha SY, Oh BK, Koo JS, Kim YJ, Choi J, Park C, Park YN.
    Am J Gastroenterol; 2004 Jan 15; 99(1):68-75. PubMed ID: 14687144
    [Abstract] [Full Text] [Related]

  • 17. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeenniemi-Hujanen T.
    Cancer Lett; 2006 May 08; 236(1):125-32. PubMed ID: 15982804
    [Abstract] [Full Text] [Related]

  • 18. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
    Unsal D, Akyurek N, Uner A, Erpolat OP, Han U, Akmansu M, Mentes BB, Dursun A.
    Am J Clin Oncol; 2008 Feb 08; 31(1):55-63. PubMed ID: 18376229
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus.
    Sano T, Shimada K, Sakamoto Y, Ojima H, Esaki M, Kosuge T.
    Ann Surg Oncol; 2008 Feb 08; 15(2):590-9. PubMed ID: 18057991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.